ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1963

Specialty of Provider Referring for Temporal Artery Biopsy Affects the Likelihood of Giant Cell Arteritis (GCA) Diagnosis

Lindsay Lally1 and Robert F. Spiera2, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Rheumatology, HSS, New York, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: biopsies, diagnosis, giant cell arteritis and temporal arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Vasculitis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Presenting signs/symptoms of GCA can be nonspecific
and patients can initially present to a spectrum of clinical specialties.  While temporal artery biopsy (TAB) is
recommended for confirming a GCA diagnosis, many patients without GCA are
referred for TAB and started on high-dose steroids while awaiting the
procedure, which can result in toxicity. 
Several studies have evaluated clinical predictors of positive TAB among
patients with suspected GCA but none have evaluated if the specialty of the
provider referring for TAB affects the likelihood of a patient ultimately being
diagnosed with GCA.

Methods: All TAB performed at a tertiary care center over 5
years were identified.  Medical
records were reviewed; those without adequate clinical information were excluded.
Whether a patient was referred for TAB by a rheumatologist, internist,
ophthalmologist, or neurologist was noted.  Subjects were categorized according to 1990 ACR criteria and
TAB status as having GCA or no GCA: those with GCA and negative TAB met ³3 ACR
criteria and were treated as GCA for at least 6mths based on reviewing chart
following TAB.

 Results: Of 188
subjects analyzed, 52 (27.7%) ultimately were recognized as having GCA.  23 (12.2%) had positive TAB and
clinical GCA, and 29 (15.4%) had negative TAB but were clinically diagnosed as
GCA.   There were a similar
number of referrals from each of the 4 specialties. Rheumatologists were
responsible for referring 28/52 (53.8%) of cases ultimately diagnosed as GCA
for TAB.  Compared to all other specialties,
rheumatologists had the highest odds of referring a case ultimately deemed to
have GCA for TAB. Patients referred by
rheumatologists had 5.43 (95% CI: 2.70, 10.99) times the odds of having GCA
compared to patients referred by internists, ophthalmologists, or neurologists
(p < 0.001).  Rheumatologists
were also more likely to have referred a patient with a positive TAB than other
specialists OR 3.41 (95% CI 1.40-8.33) p=0.007. 
Using rheumatologists as the reference group,
patients referred by internists, neurologists or ophthalmologists all had a
lower odds of being diagnosed with GCA 
(Table 1)   Adjusting
for presenting symptoms (PMR, vision loss, headache) that may cause referral
bias, patients referred for TAB by rheumatologists remained more likely than
those referred by other specialists to have GCA, OR 5.49(95% CI 2.60-11.63),
p<0.001.     

Conclusion: In this cohort, patients referred for TAB by
rheumatologists had a significantly higher likelihood of having GCA or positive
TAB compared to those referred by all other specialties.   These data may support more
wide-spread implementation of fast-track pathways, where feasible, which would permit a rheumatologic evaluation for all patients
with suspected GCA prior to TAB.

Table 1: Odds of GCA Diagnosis
By Referring Specialty

Specialty

Total Referrals for TAB, n(%)

GCA cases, n(%)

Odds ratio (95% CI)*

P-value

Rheumatology

52 (27.7)

28 (53.8)

Internal Medicine

47 (25.0)

15 (28.8)

0.40 (0.18-0.91)

0.029

Neurology

53 (28.2)

5 (9.6)

0.09 (0.03-0.26)

<0.001

Ophthalmology

36 (19.1)

4 (7.7)

0.11 (0.03-0.35)

<0.001

*Odds of having GCA compared to
patients referred by rheumatologists


Disclosure: L. Lally, None; R. F. Spiera, None.

To cite this abstract in AMA style:

Lally L, Spiera RF. Specialty of Provider Referring for Temporal Artery Biopsy Affects the Likelihood of Giant Cell Arteritis (GCA) Diagnosis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/specialty-of-provider-referring-for-temporal-artery-biopsy-affects-the-likelihood-of-giant-cell-arteritis-gca-diagnosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/specialty-of-provider-referring-for-temporal-artery-biopsy-affects-the-likelihood-of-giant-cell-arteritis-gca-diagnosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology